Ipsen released a strong set of FY17 results which were ahead of our estimates as well as market consensus. Revenue at CER surged 21.1% (100bp above AV’s estimate) led by strong growth momentum in the Specialty Care/SC segment (+25.9% vs guidance: >+24%; c.83% of sales). Within the segment, Somatuline continued to be the principal growth contributor (+31.9%; c.37% for sales) benefiting from robust volume growth in North America (+62.1%; c.47% of drug sales). Neurosciences drug ‘
21 Feb 2018
Robust finish to the year; momentum to continue into FY18 as well
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust finish to the year; momentum to continue into FY18 as well
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
21 Feb 2018 -
Author:
Sumit Sayal -
Pages:
4
Ipsen released a strong set of FY17 results which were ahead of our estimates as well as market consensus. Revenue at CER surged 21.1% (100bp above AV’s estimate) led by strong growth momentum in the Specialty Care/SC segment (+25.9% vs guidance: >+24%; c.83% of sales). Within the segment, Somatuline continued to be the principal growth contributor (+31.9%; c.37% for sales) benefiting from robust volume growth in North America (+62.1%; c.47% of drug sales). Neurosciences drug ‘